Replies to post #47496 on Sunshine Biopharma Inc (SBFM)

[LETSWIN2020]

A lot has changed since 2015 . Incase you have not noticed its 2020 heading towards 2021 in less than 6 months time.

[EOT]

Sheesh, Get out of the Past. WE ARE PAST THAT... wow.


First of all, OBVIOUSLY they got the drug or all the scientific studies couldn’t have been written as recorded since then. It’s just simply logic man...


Now into the future...lol.
1 year after sighing a contract with Crocus to make the drug Adva-27a. On Oct 17/19 Sunshine began xenograft studies in mice carrying Human Cancer.....
with the fake drug of course..lol


I personally CONFIRMED this PR through an email.......

For Immediate Release December 12, 2018

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a.

Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine’s lead anticancer compound targeted for Pancreatic Cancer.

The material which will ultimately be generated by a contract manufacturing organization will be used for animal toxicity studies and clinical trials.


About Crocus Laboratories Inc.
Crocus Laboratories Inc. is a Canadian medicinal chemistry company engaged in the design and synthesis of new chemical entities, including enzyme inhibitors, receptor modulators and compound libraries. The Crocus team has extensive experience in drug discovery and development, particularly in the areas of oncology and infectious diseases. More information about Crocus is available at www.crocuslaboratories.com.





Xenograft is the stage before HUMAN.
This xenograft is DONE...
WATCH WHAT HAPPENS NEXT$$$



For Immediate Release October 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER
Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets:

“SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice.

In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors.

Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.


About Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. In vitro tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

[Cherrypoppers]

Share price says it all